Shanghai Henlius Biotech Unveils "Globalisation 2.0" Strategy With Plans to Launch Over 20 Products Globally by 2030, Expand Innovation Pipeline, and Strengthen International Commercialisation Capabilities

Reuters01-16
<a href="https://laohu8.com/S/SGBCF">Shanghai Henlius Biotech</a> Unveils "Globalisation 2.0" <a href="https://laohu8.com/S/MSTR">Strategy</a> With Plans to Launch Over 20 Products Globally by 2030, Expand Innovation Pipeline, and Strengthen International Commercialisation Capabilities

Shanghai Henlius Biotech Inc. has announced its "Globalisation 2.0" strategy and mid-to-long-term innovation blueprint, outlining plans to expand its global biopharmaceutical footprint by 2030. The company aims to launch more than 20 products worldwide, including over 15 in the U.S. and European markets. Henlius intends to advance innovative therapeutic modalities such as antibody-drug conjugates (ADCs), multi-specific antibodies, and T-cell engagers (TCEs), targeting areas including oncology, autoimmune, metabolic, and central nervous system diseases. The company plans to further strengthen its global commercialisation capabilities and expects continued growth in international market revenue, reinforcing its position in the global biopharmaceutical industry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN65034) on January 16, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment